Last reviewed · How we verify
NCT03392402: ThyroPred-1
Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
trial in Thyroid Nodule in 599 participants. Completed in 31 December 2020.
31 March 2020
Quick facts
| Lead sponsor | Maria Sklodowska-Curie National Research Institute of Oncology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 599 |
| Start date | 1 January 2017 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Poland |
Conditions studied
- Thyroid Nodule — all drugs for Thyroid Nodule →
- Thyroid Neoplasm — all drugs for Thyroid Neoplasm →
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Who can join
18 and older, any sex, with Thyroid Nodule or Thyroid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the usefulness of molecular classifier to aid the diagnosis of malignancy in the material obtained by fine-needle aspiration biopsy (FNAB) of thyroid nodule. All participants will undergo FNAB with routine cytological assessment and molecular testing. Patients will undergo surgery or be followed-up, according to the clinical guidelines. The diagnostic power of combined molecular/clinical classifier will be compared to prediction based on clinical features only, by investigators blinded to the final diagnosis of surgical assessment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03392402
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Nodule
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07488325 — Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytol · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07287176 — Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System · NA · recruiting
- NCT06730321 — Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment · recruiting
Other Maria Sklodowska-Curie National Research Institute of Oncology trials
Trials by the same sponsor.
- NCT07216157 — NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery · NA · recruiting
- NCT06472583 — Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast C · Phase 2 · recruiting
- NCT05271162 — Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines · Phase 3 · recruiting
- NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
- NCT06128863 — Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tiss · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03392402 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maria Sklodowska-Curie National Research Institute of Oncology
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03392402.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing